Compositions Comprising Receptor-Associated Protein (RAP) Variants Specific for LRP2 and Uses Thereof
AssigneeRaptor Pharmaceutical Inc.
InventorsChristopher M. Starr, Todd C. Zankel
Life of this patent
Estimating the term…
Abstract
The present invention relates generally to receptor-selective variants of the low-density lipoprotein receptor-associated protein (RAP) and compositions thereof, methods of generating such variants and methods of using such receptor-selective RAP variant compositions for therapeutic purposes. The invention also relates to antibodies that bind to one or a small subset of CR-containing proteins.
Claims39
A polypeptide comprising an amino acid sequence variant of the alpha-2-macroglobulin/low density lipoprotein receptor-related protein-associated protein 1 (RAP) of SEQ ID NO:
- 2, wherein said amino acid sequence variant of RAP binds to LRP2 with an affinity that is at least 3-fold greater than binding to LRPP1.
A polypeptide of claim 1014 wherein said acidic amino acid is selected from the group consisting of D and E.
An antibody that binds to a CR of any one of LRP2, LRP6, VLDLR, FDC-8D6 or matriptase.
An antibody that binds to at least two repeated CR domains of any one of LRP2, LRP6, VLDLR, FDC-8D6 or matriptase.
Dependencies are inferred from the claim text.